ABHD17A

Across TCGA pan-cancer cohorts, ABHD17A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ABHD17A data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher ABHD17A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABHD17A expression acts as an unfavorable survival marker.

KICH, THCA, and PRAD are the cancer types where ABHD17A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
THCA	DFS	Median	All	0.178	0.842	.010	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ABHD17A–KICH (DFS)

Open the KICH breakdown →